<DOC>
	<DOCNO>NCT00093067</DOCNO>
	<brief_summary>The purpose study compare safety efficacy daptomycin , antibiotic , standard therapy subject infective endocarditis bacteremia due Staphylococcus aureus ( S. aureus ) .</brief_summary>
	<brief_title>Daptomycin Treatment Subjects With Infective Endocarditis Bacteremia Due S. Aureus</brief_title>
	<detailed_description>Even prompt treatment , Staphylococcus aureus Infective Endocarditis ( IE ) continue associate significant morbidity mortality indicate need new therapeutic approach . In vitro , daptomycin rapidly bactericidal , concentration-dependent killing , MIC90 0.5 microgram/ml S. aureus ; clinical study , daptomycin appear well tolerate administer every 24 hour i.v . infusion . These characteristic suggest clinically microbiologically effective treatment serious S. aureus infection , include IE bacteremia Comparison : standard care ( Vancomycin Semi-synthetic Penicillin adjunct gentamicin )</detailed_description>
	<mesh_term>Bacteremia</mesh_term>
	<mesh_term>Endocarditis</mesh_term>
	<mesh_term>Endocarditis , Bacterial</mesh_term>
	<mesh_term>Daptomycin</mesh_term>
	<criteria>Documented S. aureus bacteremia within 2 calendar day first dose study medication Subjects creatinine clearance le 30 ml/min Subjects pneumonia Pregnant , nursing , lactate Documented history allergy intolerance penicillin vancomycin Subjects osteomyelitis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Gram-positive bacterial infection</keyword>
	<keyword>Staph Aureus</keyword>
	<keyword>endocarditis</keyword>
	<keyword>bacteremia</keyword>
	<keyword>Cubist</keyword>
</DOC>